Intellia Therapeutics (NTLA) CSO logs 8,508-share sell-to-cover transaction

Rhea-AI Filing Summary

Intellia Therapeutics EVP and Chief Scientific Officer Birgit C. Schultes reported a mandatory tax-related stock sale. On January 5, 2026, she sold 8,508 shares of Intellia Therapeutics common stock at a price of $9.21 per share. A footnote explains this was a required “sell-to-cover” transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on January 1, 2026, and not a voluntary trade. Following this transaction, she beneficially owned 98,533 shares of Intellia common stock, which include 925 and 932 shares acquired under the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.

Insider Trade Summary

Net Seller: 8,508 shares ($78,359)

Net Sell 1 txn

Insider Schultes Birgit C

Role EVP, Chief Scientific Officer

Sold 8,508 shs ($78K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,508	$9.21	$78K

Holdings After Transaction: Common Stock — 98,533 shares (Direct)

Footnotes (1)

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person. Includes 925 and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schultes Birgit C

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET, SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		8,508	D	$9.21	98,533(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

2. Includes 925 and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.

	James Basta, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Intellia Therapeutics (NTLA) report for Birgit C. Schultes?

On January 5, 2026, EVP and Chief Scientific Officer Birgit C. Schultes reported the sale of 8,508 shares of Intellia Therapeutics common stock at $9.21 per share.

Was the NTLA insider sale by Birgit C. Schultes a discretionary trade?

No. A footnote states the sale was a mandatory "sell-to-cover" transaction to satisfy tax withholding obligations upon the vesting of RSUs on January 1, 2026, and it was not a volitional trade by the reporting person.

How many Intellia Therapeutics (NTLA) shares does Birgit C. Schultes hold after the reported transaction?

After the transaction, Birgit C. Schultes beneficially owned 98,533 shares of Intellia Therapeutics common stock.

At what price were the NTLA shares sold in this Form 4 filing?

The 8,508 shares of Intellia Therapeutics common stock were sold at a price of $9.21 per share.

What is Birgit C. Schultes’s role at Intellia Therapeutics (NTLA)?

Birgit C. Schultes is an officer of Intellia Therapeutics, serving as EVP, Chief Scientific Officer, according to the filing.

What additional NTLA shares are included in Birgit C. Schultes’s reported holdings?

Her 98,533-share holding includes 925 shares and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.